Rpdlab Spółka z Ograniczoną Odpowiedzialnością (KRS 0000906042, NIP 5213931989) is a Polish company, headquartered in Warszawa, Mazowieckie voivodeship. RPDLAB operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since June 15, 2021. RPDLAB's most recently reported net revenue was 0 PLN for 2021.
No reported revenue
The company reported no revenue in any available reporting year. This may indicate a non-operating entity.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Rpdlab
Identity
- Name
- Rpdlab Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- June 15, 2021
- Registry status as of
- November 20, 2025
- Latest entry
- September 27, 2022
- Founding act
- 09.06.2021R.
Articles of association history (2)
- June 9, 2021: 09.06.2021R.
- June 18, 2021: 18.06.2021 R., REP. A NR 22712/2021, NOTARIUSZ GRZEGORZ GILER, KANCELARIA NOTARIALNA W WARSZAWIE, UCHYLENIE I PRZYJĘCIE NOWEJ TREŚCI UMOWY
Activities
Other activities
Address and contact
- Address
- UL. BOBROWIECKA, 1A, 302,303, 00-728, WARSZAWA, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- WARSZAWA
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
- Coordinates
- 52.2298, 21.0117approx.
Risk and payment profile - Rpdlab
Credibility rating
35.4 / 100
Poor credibility
Insolvency risk
Low
Elevated threat
Closure risk
42
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
1
1/5 yrs
Board changes
0
0/5 yrs
PKD changes
0
0/5 yrs
Name changes
0
0/5 yrs
Data from 5 years of registry activity.
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Rpdlab
Founded
June 15, 2021
5 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
WARSZAWA
MAZOWIECKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
50.0 K PLN
1,000 shares total
Shareholders
2
shareholders
Board
1 person
Filed years
1 year
2021 · profitable: 0/1
Registry entries
6
latest: September 27, 2022
Risk signals
Revenue
0 PLN
2021
Net profit
-62.4 K PLN
2021
Assets
855.5 K PLN
2021
Equity
187.6 K PLN
2021
Valuation
635.6 K PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Rpdlab.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
